{
  "id": "42_ref_0",
  "query": "对象：Floxuridine（5-氟脱氧尿苷）；SMILES：OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O。已知理化性质：MW=246.2、logP=-0.9、TPSA=92.0、HBD=3、HBA=5、RB=4。3D几何优化：方法ETKDG、力场MMFF、最大迭代500、收敛=true、总能量72.8 kcal/mol。3D形状描述符：Rg=2.35、PMI=[120.4, 230.8, 350.9]、asphericity=0.24、eccentricity=0.78。合成可及性原始分数：SAS_raw=4.7。可视化路径：2D=\"/images/Floxuridine_2D.png\"；3D=\"/models/Floxuridine_3D.sdf\"。\n(1) 报告MW、logP、TPSA、HBD、HBA、RB，并对Lipinski五规则进行两次独立评估，分别给出违例数，说明两次结果是否相同。\n(2) 报告3D几何优化的方法、力场、最大迭代、收敛与总能量，并给出Rg、PMI、asphericity、eccentricity。\n(3) 将SAS_raw按四舍五入保留1位小数，给出最终SAS分数，并说明来源为题面给定且进行[1,10]范围检查。\n(4) 给出2D/3D结构图路径，并说明其用于核对嘧啶5位氟取代与糖环手性（相对构型）。\n(5) 提供数值汇总与交叉校验清单（含SAS范围检查、理化属性重复评估结果是否相同、形状与理化属性的合理性说明），并给出总体成药性结论与最终SAS。\n结果以数值形式报告；SAS保留1位小数；所有量按题面给定单位与数值呈现；未注明单位的量视为无单位。",
  "model": "gpt-4o-20241120",
  "use_tools": true,
  "mode": "tool_mode",
  "rounds": 1,
  "messages": [
    {
      "role": "user",
      "content": "对象：Floxuridine（5-氟脱氧尿苷）；SMILES：OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O。已知理化性质：MW=246.2、logP=-0.9、TPSA=92.0、HBD=3、HBA=5、RB=4。3D几何优化：方法ETKDG、力场MMFF、最大迭代500、收敛=true、总能量72.8 kcal/mol。3D形状描述符：Rg=2.35、PMI=[120.4, 230.8, 350.9]、asphericity=0.24、eccentricity=0.78。合成可及性原始分数：SAS_raw=4.7。可视化路径：2D=\"/images/Floxuridine_2D.png\"；3D=\"/models/Floxuridine_3D.sdf\"。\n(1) 报告MW、logP、TPSA、HBD、HBA、RB，并对Lipinski五规则进行两次独立评估，分别给出违例数，说明两次结果是否相同。\n(2) 报告3D几何优化的方法、力场、最大迭代、收敛与总能量，并给出Rg、PMI、asphericity、eccentricity。\n(3) 将SAS_raw按四舍五入保留1位小数，给出最终SAS分数，并说明来源为题面给定且进行[1,10]范围检查。\n(4) 给出2D/3D结构图路径，并说明其用于核对嘧啶5位氟取代与糖环手性（相对构型）。\n(5) 提供数值汇总与交叉校验清单（含SAS范围检查、理化属性重复评估结果是否相同、形状与理化属性的合理性说明），并给出总体成药性结论与最终SAS。\n结果以数值形式报告；SAS保留1位小数；所有量按题面给定单位与数值呈现；未注明单位的量视为无单位。"
    },
    {
      "role": "assistant",
      "content": "### Floxuridine 数值报告与分析\n\n#### (1) 理化性质与Lipinski五规则评估\n- **分子量 (MW)**: 246.2  \n- **logP**: -0.9  \n- **拓扑极表面积 (TPSA)**: 92.0  \n- **氢键供体数量 (HBD)**: 3  \n- **氢键受体数量 (HBA)**: 5  \n- **旋转键数量 (RB)**: 4  \n\n**Lipinski五规则评估**：\n- Lipinski规则包括以下要求：\n  1. 分子量 ≤ 500  \n  2. logP ≤ 5  \n  3. 氢键供体数量 (HBD) ≤ 5  \n  4. 氢键受体数量 (HBA) ≤ 10  \n  5. 旋转键数量 (RB) ≤ 10  \n\n**评估结果**：  \n1. 第一次评估：无违例（0项违例）。  \n2. 第二次评估：再次确认，无违例（0项违例）。  \n\n两次评估结果一致，无违例。\n\n---\n\n#### (2) 3D优化与形状描述符\n- **优化方法**: ETKDG  \n- **力场**: MMFF  \n- **最大迭代次数**: 500  \n- **收敛**: true  \n- **总能量**: 72.8 kcal/mol  \n\n**3D形状描述符**：\n- 回转半径 (Rg): 2.35  \n- 主惯性矩 (PMI): [120.4, 230.8, 350.9]  \n- 非球形性 (asphericity): 0.24  \n- 偏心率 (eccentricity): 0.78  \n\n---\n\n#### (3) SAS分数\n- **原始SAS分数 (SAS_raw)**: 4.7  \n- **最终SAS分数 (四舍五入保留1位小数)**: 4.7  \n- **来源说明**: 题面给定，且经检查确认在合理范围 [1,10] 内。\n\n---\n\n#### (4) 2D/3D结构图路径\n- **2D结构图路径**: \"/images/Floxuridine_2D.png\"  \n- **3D结构图路径**: \"/models/Floxuridine_3D.sdf\"  \n\n**用途说明**:  \n用于核对：\n1. 嘧啶环5位是否正确氟取代。  \n2. 糖环手性（相对构型）是否正确。\n\n---\n\n#### (5) 数值汇总与交叉校验清单\n1. **SAS范围检查**: SAS_raw为4.7，处于合理范围 [1,10]。  \n2. **理化属性重复评估**: 题面提供属性与Lipinski规则独立评估结果完全一致。无违例。  \n3. **形状与理化属性的合理性说明**:  \n   - Floxuridine的回转半径 (Rg=2.35) 和非球形性 (asphericity=0.24) 表明分子形状接近对称，符合其化学结构特点。  \n   - TPSA为92.0，说明分子有适中的极性，与其作为抗癌药物的性质一致。  \n\n---\n\n#### 总体成药性结论与最终SAS\n- **总体成药性结论**:  \n  Floxuridine符合Lipinski五规则，形状与理化属性合理，合成可及性分数适中（SAS=4.7），具有良好的成药性潜力。  \n\n- **最终SAS分数**: 4.7"
    },
    {
      "role": "user",
      "content": "现在请仅输出严格 JSON，必须完全匹配以下结构（键名、层级、字段齐全），所有数值用数字表示（保留2-3位小数），布尔用 true/false，字符串填写说明文字。不要输出任何解释文字或前后缀，也不要多余字段；若无法计算某值请给出可解析的近似值。\n\n{\n  \"(1)\": {\n    \"MW\": \"[数值]\",\n    \"logP\": \"[数值]\",\n    \"TPSA\": \"[数值]\",\n    \"HBD\": \"[数值]\",\n    \"HBA\": \"[数值]\",\n    \"RB\": \"[数值]\",\n    \"Lipinski_violations_eval_1\": \"[数值]\",\n    \"Lipinski_violations_eval_2\": \"[数值]\",\n    \"result_relation\": \"[字符串]\"\n  },\n  \"(2)\": {\n    \"optimization_method\": \"[字符串]\",\n    \"force_field\": \"[字符串]\",\n    \"max_iterations\": \"[数值]\",\n    \"converged\": \"[布尔值]\",\n    \"total_energy\": \"[字符串]\",\n    \"Rg\": \"[数值]\",\n    \"PMI\": \"[3个数值的数组]\",\n    \"asphericity\": \"[数值]\",\n    \"eccentricity\": \"[数值]\"\n  },\n  \"(3)\": {\n    \"SAS_raw\": \"[数值]\",\n    \"SAS_final_1dp\": \"[数值]\",\n    \"source\": \"[字符串]\",\n    \"range_check\": \"[字符串]\"\n  },\n  \"(4)\": {\n    \"path_2D\": \"[字符串]\",\n    \"path_3D\": \"[字符串]\",\n    \"usage\": \"[字符串]\"\n  },\n  \"(5)\": {\n    \"summary_index\": {\n      \"P1\": \"[字符串]\",\n      \"G1\": \"[字符串]\",\n      \"S1\": \"[字符串]\",\n      \"Paths\": \"[字符串]\"\n    },\n    \"cross_checks\": \"[3个字符串的数组]\",\n    \"overall_conclusion\": \"[字符串]\"\n  }\n}"
    },
    {
      "role": "assistant",
      "content": "{\n  \"(1)\": {\n    \"MW\": 246.2,\n    \"logP\": -0.9,\n    \"TPSA\": 92.0,\n    \"HBD\": 3,\n    \"HBA\": 5,\n    \"RB\": 4,\n    \"Lipinski_violations_eval_1\": 0,\n    \"Lipinski_violations_eval_2\": 0,\n    \"result_relation\": \"Two evaluations are consistent\"\n  },\n  \"(2)\": {\n    \"optimization_method\": \"ETKDG\",\n    \"force_field\": \"MMFF\",\n    \"max_iterations\": 500,\n    \"converged\": true,\n    \"total_energy\": \"72.8 kcal/mol\",\n    \"Rg\": 2.35,\n    \"PMI\": [120.4, 230.8, 350.9],\n    \"asphericity\": 0.24,\n    \"eccentricity\": 0.78\n  },\n  \"(3)\": {\n    \"SAS_raw\": 4.7,\n    \"SAS_final_1dp\": 4.7,\n    \"source\": \"Provided in prompt\",\n    \"range_check\": \"Passed (1-10)\"\n  },\n  \"(4)\": {\n    \"path_2D\": \"/images/Floxuridine_2D.png\",\n    \"path_3D\": \"/models/Floxuridine_3D.sdf\",\n    \"usage\": \"Verify fluorine substitution on pyrimidine and sugar chirality\"\n  },\n  \"(5)\": {\n    \"summary_index\": {\n      \"P1\": \"Lipinski evaluation consistent\",\n      \"G1\": \"Shape descriptors reasonable\",\n      \"S1\": \"SAS score validated\",\n      \"Paths\": \"Structural paths consistent with molecule\"\n    },\n    \"cross_checks\": [\"SAS range check passed\", \"No Lipinski violations\", \"Shape matches structure\"],\n    \"overall_conclusion\": \"Drug-like molecule with moderate synthetic accessibility\"\n  }\n}"
    }
  ],
  "answer_template": {
    "(1)": {
      "MW": "[数值]",
      "logP": "[数值]",
      "TPSA": "[数值]",
      "HBD": "[数值]",
      "HBA": "[数值]",
      "RB": "[数值]",
      "Lipinski_violations_eval_1": "[数值]",
      "Lipinski_violations_eval_2": "[数值]",
      "result_relation": "[字符串]"
    },
    "(2)": {
      "optimization_method": "[字符串]",
      "force_field": "[字符串]",
      "max_iterations": "[数值]",
      "converged": "[布尔值]",
      "total_energy": "[字符串]",
      "Rg": "[数值]",
      "PMI": "[3个数值的数组]",
      "asphericity": "[数值]",
      "eccentricity": "[数值]"
    },
    "(3)": {
      "SAS_raw": "[数值]",
      "SAS_final_1dp": "[数值]",
      "source": "[字符串]",
      "range_check": "[字符串]"
    },
    "(4)": {
      "path_2D": "[字符串]",
      "path_3D": "[字符串]",
      "usage": "[字符串]"
    },
    "(5)": {
      "summary_index": {
        "P1": "[字符串]",
        "G1": "[字符串]",
        "S1": "[字符串]",
        "Paths": "[字符串]"
      },
      "cross_checks": "[3个字符串的数组]",
      "overall_conclusion": "[字符串]"
    }
  },
  "golden_standard": {
    "(1)": {
      "MW": 246.2,
      "logP": -0.9,
      "TPSA": 92.0,
      "HBD": 3,
      "HBA": 5,
      "RB": 4,
      "Lipinski_violations_eval_1": 0,
      "Lipinski_violations_eval_2": 0,
      "result_relation": "两次结果相同（均满足规则）"
    },
    "(2)": {
      "optimization_method": "ETKDG",
      "force_field": "MMFF",
      "max_iterations": 500,
      "converged": true,
      "total_energy": "72.8 kcal/mol",
      "Rg": 2.35,
      "PMI": [
        120.4,
        230.8,
        350.9
      ],
      "asphericity": 0.24,
      "eccentricity": 0.78
    },
    "(3)": {
      "SAS_raw": 4.7,
      "SAS_final_1dp": 4.7,
      "source": "题面给定SAS_raw",
      "range_check": "[1,10]内"
    },
    "(4)": {
      "path_2D": "/images/Floxuridine_2D.png",
      "path_3D": "/models/Floxuridine_3D.sdf",
      "usage": "2D用于定位嘧啶5位F取代；3D用于查看糖环立体中心以核对手性"
    },
    "(5)": {
      "summary_index": {
        "P1": "(1)中的理化性质与Lipinski评估结果",
        "G1": "(2)中的几何优化与形状描述符",
        "S1": "(3)中的最终SAS",
        "Paths": "(4)中的2D/3D路径"
      },
      "cross_checks": [
        "SAS范围：S1∈[1,10]",
        "Lipinski两次评估结果相同，均满足规则",
        "理化性质与形状合理性：低logP与较高TPSA提示亲水性；PMI与asphericity显示非球形核苷骨架，符合含糖嘧啶结构特征"
      ],
      "overall_conclusion": "满足Lipinski五规则且两次评估相同；SAS为S1，显示中等合成可及性；具备口服药物样特征"
    }
  },
  "expected_format": "structured_json",
  "model_structured_answer": {
    "(1)": {
      "MW": 246.2,
      "logP": -0.9,
      "TPSA": 92.0,
      "HBD": 3,
      "HBA": 5,
      "RB": 4,
      "Lipinski_violations_eval_1": 0,
      "Lipinski_violations_eval_2": 0,
      "result_relation": "Two evaluations are consistent"
    },
    "(2)": {
      "optimization_method": "ETKDG",
      "force_field": "MMFF",
      "max_iterations": 500,
      "converged": true,
      "total_energy": "72.8 kcal/mol",
      "Rg": 2.35,
      "PMI": [
        120.4,
        230.8,
        350.9
      ],
      "asphericity": 0.24,
      "eccentricity": 0.78
    },
    "(3)": {
      "SAS_raw": 4.7,
      "SAS_final_1dp": 4.7,
      "source": "Provided in prompt",
      "range_check": "Passed (1-10)"
    },
    "(4)": {
      "path_2D": "/images/Floxuridine_2D.png",
      "path_3D": "/models/Floxuridine_3D.sdf",
      "usage": "Verify fluorine substitution on pyrimidine and sugar chirality"
    },
    "(5)": {
      "summary_index": {
        "P1": "Lipinski evaluation consistent",
        "G1": "Shape descriptors reasonable",
        "S1": "SAS score validated",
        "Paths": "Structural paths consistent with molecule"
      },
      "cross_checks": [
        "SAS range check passed",
        "No Lipinski violations",
        "Shape matches structure"
      ],
      "overall_conclusion": "Drug-like molecule with moderate synthetic accessibility"
    }
  },
  "answer_extraction_success": true,
  "model_raw_answer": "{\n  \"(1)\": {\n    \"MW\": 246.2,\n    \"logP\": -0.9,\n    \"TPSA\": 92.0,\n    \"HBD\": 3,\n    \"HBA\": 5,\n    \"RB\": 4,\n    \"Lipinski_violations_eval_1\": 0,\n    \"Lipinski_violations_eval_2\": 0,\n    \"result_relation\": \"Two evaluations are consistent\"\n  },\n  \"(2)\": {\n    \"optimization_method\": \"ETKDG\",\n    \"force_field\": \"MMFF\",\n    \"max_iterations\": 500,\n    \"converged\": true,\n    \"total_energy\": \"72.8 kcal/mol\",\n    \"Rg\": 2.35,\n    \"PMI\": [120.4, 230.8, 350.9],\n    \"asphericity\": 0.24,\n    \"eccentricity\": 0.78\n  },\n  \"(3)\": {\n    \"SAS_raw\": 4.7,\n    \"SAS_final_1dp\": 4.7,\n    \"source\": \"Provided in prompt\",\n    \"range_check\": \"Passed (1-10)\"\n  },\n  \"(4)\": {\n    \"path_2D\": \"/images/Floxuridine_2D.png\",\n    \"path_3D\": \"/models/Floxuridine_3D.sdf\",\n    \"usage\": \"Verify fluorine substitution on pyrimidine and sugar chirality\"\n  },\n  \"(5)\": {\n    \"summary_index\": {\n      \"P1\": \"Lipinski evaluation consistent\",\n      \"G1\": \"Shape descriptors reasonable\",\n      \"S1\": \"SAS score validated\",\n      \"Paths\": \"Structural paths consistent with molecule\"\n    },\n    \"cross_checks\": [\"SAS range check passed\", \"No Lipinski violations\", \"Shape matches structure\"],\n    \"overall_conclusion\": \"Drug-like molecule with moderate synthetic accessibility\"\n  }\n}",
  "model_last_assistant_message": {
    "role": "assistant",
    "content": "{\n  \"(1)\": {\n    \"MW\": 246.2,\n    \"logP\": -0.9,\n    \"TPSA\": 92.0,\n    \"HBD\": 3,\n    \"HBA\": 5,\n    \"RB\": 4,\n    \"Lipinski_violations_eval_1\": 0,\n    \"Lipinski_violations_eval_2\": 0,\n    \"result_relation\": \"Two evaluations are consistent\"\n  },\n  \"(2)\": {\n    \"optimization_method\": \"ETKDG\",\n    \"force_field\": \"MMFF\",\n    \"max_iterations\": 500,\n    \"converged\": true,\n    \"total_energy\": \"72.8 kcal/mol\",\n    \"Rg\": 2.35,\n    \"PMI\": [120.4, 230.8, 350.9],\n    \"asphericity\": 0.24,\n    \"eccentricity\": 0.78\n  },\n  \"(3)\": {\n    \"SAS_raw\": 4.7,\n    \"SAS_final_1dp\": 4.7,\n    \"source\": \"Provided in prompt\",\n    \"range_check\": \"Passed (1-10)\"\n  },\n  \"(4)\": {\n    \"path_2D\": \"/images/Floxuridine_2D.png\",\n    \"path_3D\": \"/models/Floxuridine_3D.sdf\",\n    \"usage\": \"Verify fluorine substitution on pyrimidine and sugar chirality\"\n  },\n  \"(5)\": {\n    \"summary_index\": {\n      \"P1\": \"Lipinski evaluation consistent\",\n      \"G1\": \"Shape descriptors reasonable\",\n      \"S1\": \"SAS score validated\",\n      \"Paths\": \"Structural paths consistent with molecule\"\n    },\n    \"cross_checks\": [\"SAS range check passed\", \"No Lipinski violations\", \"Shape matches structure\"],\n    \"overall_conclusion\": \"Drug-like molecule with moderate synthetic accessibility\"\n  }\n}"
  },
  "evaluation_score": 0.8571428571428571,
  "evaluation_summary": "匹配字段: 30/35 (得分: 85.71%)",
  "evaluation_details": {
    "(1).MW": {
      "path": "(1).MW",
      "expected": 246.2,
      "actual": 246.2,
      "expected_num": 246.2,
      "actual_num": 246.2,
      "status": "match",
      "match_type": "exact"
    },
    "(1).logP": {
      "path": "(1).logP",
      "expected": -0.9,
      "actual": -0.9,
      "expected_num": -0.9,
      "actual_num": -0.9,
      "status": "match",
      "match_type": "exact"
    },
    "(1).TPSA": {
      "path": "(1).TPSA",
      "expected": 92.0,
      "actual": 92.0,
      "expected_num": 92.0,
      "actual_num": 92.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).HBD": {
      "path": "(1).HBD",
      "expected": 3,
      "actual": 3,
      "expected_num": 3.0,
      "actual_num": 3.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).HBA": {
      "path": "(1).HBA",
      "expected": 5,
      "actual": 5,
      "expected_num": 5.0,
      "actual_num": 5.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).RB": {
      "path": "(1).RB",
      "expected": 4,
      "actual": 4,
      "expected_num": 4.0,
      "actual_num": 4.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).Lipinski_violations_eval_1": {
      "path": "(1).Lipinski_violations_eval_1",
      "expected": 0,
      "actual": 0,
      "expected_num": 0.0,
      "actual_num": 0.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).Lipinski_violations_eval_2": {
      "path": "(1).Lipinski_violations_eval_2",
      "expected": 0,
      "actual": 0,
      "expected_num": 0.0,
      "actual_num": 0.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).result_relation": {
      "path": "(1).result_relation",
      "expected": "两次结果相同（均满足规则）",
      "actual": "Two evaluations are consistent",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(2).optimization_method": {
      "path": "(2).optimization_method",
      "expected": "ETKDG",
      "actual": "ETKDG",
      "status": "match",
      "match_type": "exact"
    },
    "(2).force_field": {
      "path": "(2).force_field",
      "expected": "MMFF",
      "actual": "MMFF",
      "status": "match",
      "match_type": "exact"
    },
    "(2).max_iterations": {
      "path": "(2).max_iterations",
      "expected": 500,
      "actual": 500,
      "expected_num": 500.0,
      "actual_num": 500.0,
      "status": "match",
      "match_type": "exact"
    },
    "(2).converged": {
      "path": "(2).converged",
      "expected": true,
      "actual": true,
      "expected_num": 1.0,
      "actual_num": 1.0,
      "status": "match",
      "match_type": "exact"
    },
    "(2).total_energy": {
      "path": "(2).total_energy",
      "expected": "72.8 kcal/mol",
      "actual": "72.8 kcal/mol",
      "status": "match",
      "match_type": "exact"
    },
    "(2).Rg": {
      "path": "(2).Rg",
      "expected": 2.35,
      "actual": 2.35,
      "expected_num": 2.35,
      "actual_num": 2.35,
      "status": "match",
      "match_type": "exact"
    },
    "(2).PMI[0]": {
      "path": "(2).PMI[0]",
      "expected": 120.4,
      "actual": 120.4,
      "expected_num": 120.4,
      "actual_num": 120.4,
      "status": "match",
      "match_type": "exact"
    },
    "(2).PMI[1]": {
      "path": "(2).PMI[1]",
      "expected": 230.8,
      "actual": 230.8,
      "expected_num": 230.8,
      "actual_num": 230.8,
      "status": "match",
      "match_type": "exact"
    },
    "(2).PMI[2]": {
      "path": "(2).PMI[2]",
      "expected": 350.9,
      "actual": 350.9,
      "expected_num": 350.9,
      "actual_num": 350.9,
      "status": "match",
      "match_type": "exact"
    },
    "(2).asphericity": {
      "path": "(2).asphericity",
      "expected": 0.24,
      "actual": 0.24,
      "expected_num": 0.24,
      "actual_num": 0.24,
      "status": "match",
      "match_type": "exact"
    },
    "(2).eccentricity": {
      "path": "(2).eccentricity",
      "expected": 0.78,
      "actual": 0.78,
      "expected_num": 0.78,
      "actual_num": 0.78,
      "status": "match",
      "match_type": "exact"
    },
    "(3).SAS_raw": {
      "path": "(3).SAS_raw",
      "expected": 4.7,
      "actual": 4.7,
      "expected_num": 4.7,
      "actual_num": 4.7,
      "status": "match",
      "match_type": "exact"
    },
    "(3).SAS_final_1dp": {
      "path": "(3).SAS_final_1dp",
      "expected": 4.7,
      "actual": 4.7,
      "expected_num": 4.7,
      "actual_num": 4.7,
      "status": "match",
      "match_type": "exact"
    },
    "(3).source": {
      "path": "(3).source",
      "expected": "题面给定SAS_raw",
      "actual": "Provided in prompt",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(3).range_check": {
      "path": "(3).range_check",
      "expected": "[1,10]内",
      "actual": "Passed (1-10)",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(4).path_2D": {
      "path": "(4).path_2D",
      "expected": "/images/Floxuridine_2D.png",
      "actual": "/images/Floxuridine_2D.png",
      "status": "match",
      "match_type": "exact"
    },
    "(4).path_3D": {
      "path": "(4).path_3D",
      "expected": "/models/Floxuridine_3D.sdf",
      "actual": "/models/Floxuridine_3D.sdf",
      "status": "match",
      "match_type": "exact"
    },
    "(4).usage": {
      "path": "(4).usage",
      "expected": "2D用于定位嘧啶5位F取代；3D用于查看糖环立体中心以核对手性",
      "actual": "Verify fluorine substitution on pyrimidine and sugar chirality",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).summary_index.P1": {
      "path": "(5).summary_index.P1",
      "expected": "(1)中的理化性质与Lipinski评估结果",
      "actual": "Lipinski evaluation consistent",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).summary_index.G1": {
      "path": "(5).summary_index.G1",
      "expected": "(2)中的几何优化与形状描述符",
      "actual": "Shape descriptors reasonable",
      "status": "mismatch",
      "match_type": "secondary_llm_failed"
    },
    "(5).summary_index.S1": {
      "path": "(5).summary_index.S1",
      "expected": "(3)中的最终SAS",
      "actual": "SAS score validated",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).summary_index.Paths": {
      "path": "(5).summary_index.Paths",
      "expected": "(4)中的2D/3D路径",
      "actual": "Structural paths consistent with molecule",
      "status": "mismatch",
      "match_type": "secondary_llm_failed"
    },
    "(5).cross_checks[0]": {
      "path": "(5).cross_checks[0]",
      "expected": "SAS范围：S1∈[1,10]",
      "actual": "SAS range check passed",
      "status": "mismatch",
      "match_type": "secondary_llm_failed"
    },
    "(5).cross_checks[1]": {
      "path": "(5).cross_checks[1]",
      "expected": "Lipinski两次评估结果相同，均满足规则",
      "actual": "No Lipinski violations",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).cross_checks[2]": {
      "path": "(5).cross_checks[2]",
      "expected": "理化性质与形状合理性：低logP与较高TPSA提示亲水性；PMI与asphericity显示非球形核苷骨架，符合含糖嘧啶结构特征",
      "actual": "Shape matches structure",
      "status": "mismatch",
      "match_type": "secondary_llm_failed"
    },
    "(5).overall_conclusion": {
      "path": "(5).overall_conclusion",
      "expected": "满足Lipinski五规则且两次评估相同；SAS为S1，显示中等合成可及性；具备口服药物样特征",
      "actual": "Drug-like molecule with moderate synthetic accessibility",
      "status": "mismatch",
      "match_type": "secondary_llm_failed"
    }
  },
  "metadata": {
    "subject": "化学",
    "topic": "药物化学与合成可及性",
    "image_path": [],
    "solution_steps": [
      "【分子识别与解析】解析5-Fluorodeoxyuridine的SMILES字符串：OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O",
      "【SAS计算】调用 calculate_synthetic_accessibility(smiles) 使用Ertl-Schuffenhauer算法计算合成可及性分数",
      "SAS基于分子复杂度、环系统、立体化学和已知合成片段进行统计评估",
      "获得SAS = 3.5，对应\"相对容易合成\"（2.0-4.0范围）",
      "【理化性质分析】调用 mol_basic_physicochemical_info(smiles) 获取完整的分子信息",
      "分子式：C9H11FN2O5，分子量：246.07 g/mol",
      "LogP = -1.68（亲水性强），TPSA = 104.55 Å²（极性表面积大）",
      "氢键供体：3，氢键受体：6，可旋转键：2",
      "芳香环：1（嘧啶环），总环数：2（嘧啶环+糖环）",
      "【Lipinski成药性评估】检查Lipinski五规则的违规情况",
      "✓ MW(246.07) ≤ 500，✓ LogP(-1.68) ≤ 5，✓ HBD(3) ≤ 5，✓ HBA(6) ≤ 10",
      "违规数 = 0，类药性 = ✓ 是",
      "【3D可视化】调用 chem_visualizer 生成2D结构图和3D投影图",
      "生成图像：5_Fluorodeoxyuridine_2d.png（平面结构）",
      "5_Fluorodeoxyuridine_3d_projection.png（3D投影）",
      "5_Fluorodeoxyuridine_3d_matplotlib.png（3D立体图）",
      "【3D结构优化】调用 optimize_geometry(smiles, method='ETKDGv3', force_field='MMFF', max_iters=200)",
      "初始能量：-0.55 kcal/mol → 优化后能量：-30.79 kcal/mol",
      "能量降低：ΔE = -30.24 kcal/mol（结构显著稳定化）",
      "【3D性质计算】调用 get_3d_properties(smiles, method='ETKDGv3', conf_id=0)",
      "主惯性矩：PMI1=496.58, PMI2=2099.67, PMI3=2215.85 amu·Ų",
      "归一化惯性矩比：NPR1=0.224, NPR2=0.948",
      "分子形状：极端棒状/纤维状（NPR1<0.5, NPR2>0.95）",
      "回转半径：Rg = 3.126 Å（分子尺寸的特征长度）",
      "非球形度：asphericity = 0.478（显著偏离球形）",
      "偏心率：eccentricity = 0.975（高度拉伸的椭球形）",
      "【合成难度评估】根据SAS=3.5给出合成难度评价",
      "合成难度：相对容易合成（★★☆☆☆）",
      "核苷类似物的典型复杂度，适合药物开发",
      "【药物应用背景】5-FdU是胸苷酸合成酶抑制剂，用于治疗结直肠癌和肝癌",
      "商品名：Floxuridine, FUDR",
      "作用机制：干扰DNA合成，诱导癌细胞凋亡",
      "【最终答案】合成可及性分数 SAS = 3.5"
    ],
    "tool_expected": [
      "calculate_synthetic_accessibility",
      "mol_basic_physicochemical_info",
      "chem_visualizer",
      "optimize_geometry",
      "get_3d_properties"
    ],
    "golden_answer": [
      {
        "(1)": {
          "MW": 246.2,
          "logP": -0.9,
          "TPSA": 92.0,
          "HBD": 3,
          "HBA": 5,
          "RB": 4,
          "Lipinski_violations_eval_1": 0,
          "Lipinski_violations_eval_2": 0,
          "result_relation": "两次结果相同（均满足规则）"
        },
        "(2)": {
          "optimization_method": "ETKDG",
          "force_field": "MMFF",
          "max_iterations": 500,
          "converged": true,
          "total_energy": "72.8 kcal/mol",
          "Rg": 2.35,
          "PMI": [
            120.4,
            230.8,
            350.9
          ],
          "asphericity": 0.24,
          "eccentricity": 0.78
        },
        "(3)": {
          "SAS_raw": 4.7,
          "SAS_final_1dp": 4.7,
          "source": "题面给定SAS_raw",
          "range_check": "[1,10]内"
        },
        "(4)": {
          "path_2D": "/images/Floxuridine_2D.png",
          "path_3D": "/models/Floxuridine_3D.sdf",
          "usage": "2D用于定位嘧啶5位F取代；3D用于查看糖环立体中心以核对手性"
        },
        "(5)": {
          "summary_index": {
            "P1": "(1)中的理化性质与Lipinski评估结果",
            "G1": "(2)中的几何优化与形状描述符",
            "S1": "(3)中的最终SAS",
            "Paths": "(4)中的2D/3D路径"
          },
          "cross_checks": [
            "SAS范围：S1∈[1,10]",
            "Lipinski两次评估结果相同，均满足规则",
            "理化性质与形状合理性：低logP与较高TPSA提示亲水性；PMI与asphericity显示非球形核苷骨架，符合含糖嘧啶结构特征"
          ],
          "overall_conclusion": "满足Lipinski五规则且两次评估相同；SAS为S1，显示中等合成可及性；具备口服药物样特征"
        }
      }
    ],
    "original_question_id": "42",
    "test_type": "refined"
  },
  "metadata_summary": {
    "subject": "化学",
    "topic": "药物化学与合成可及性",
    "test_type": "refined",
    "original_question_id": "42",
    "subject_topic_key": "化学::药物化学与合成可及性"
  },
  "evaluation_score_segments": {
    "0_25": 1.0,
    "0_50": 1.0,
    "0_75": 1.0,
    "0_100": 0.8571428571428571
  }
}